Injectable medications are exempt from the 3-1-1 liquids rule
With once-daily liraglutide, another GLP-1 receptor agonist approved for the treatment of type 2 diabetes at doses of up to 1.8 mg, body weight and sex were found to be the most important covariates for exposure which, however, did not influence liraglutide PK to any clinically relevant degree [13]
All three contain the same molecule at different doses and formulations
and a manufacturing operation in Dallas that produces injectable drugs prone to shortage
For most patients, GLP-1-related bloating often improves after dose stabilization, though timelines vary considerably between individuals
Does this mean that we have to resign ourselves to treating obesity for life, a bit like controlling hypertension, excess blood cholesterol or even insulin deficiency, with the help of drugs that should be administered continuously from the onset of pathologies